These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
457 related articles for article (PubMed ID: 23130020)
1. Current progress of RNA aptamer-based therapeutics. Zhou J; Bobbin ML; Burnett JC; Rossi JJ Front Genet; 2012; 3():234. PubMed ID: 23130020 [TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of cell-internalizing aptamers. Zhou J; Rossi JJ Curr Top Med Chem; 2009; 9(12):1144-57. PubMed ID: 19860714 [TBL] [Abstract][Full Text] [Related]
3. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. Zhou J; Li H; Zhang J; Piotr S; Rossi J J Vis Exp; 2011 Jun; (52):. PubMed ID: 21730942 [TBL] [Abstract][Full Text] [Related]
4. Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles. Sivakumar P; Kim S; Kang HC; Shim MS Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2019 May; 11(3):e1543. PubMed ID: 30070426 [TBL] [Abstract][Full Text] [Related]
5. Applications of Cancer Cell-Specific Aptamers in Targeted Delivery of Anticancer Therapeutic Agents. Kim M; Kim DM; Kim KS; Jung W; Kim DE Molecules; 2018 Apr; 23(4):. PubMed ID: 29617327 [TBL] [Abstract][Full Text] [Related]
7. [Efficient screening for 8-oxoguanine DNA glycosylase binding aptamers via capillary electrophoresis]. Han S; Zhao L; Yang G; Qu F Se Pu; 2021 Jul; 39(7):721-729. PubMed ID: 34227370 [TBL] [Abstract][Full Text] [Related]
8. Chimeric aptamers in cancer cell-targeted drug delivery. Kanwar JR; Roy K; Kanwar RK Crit Rev Biochem Mol Biol; 2011 Dec; 46(6):459-77. PubMed ID: 21955150 [TBL] [Abstract][Full Text] [Related]
9. Oligonucleotide aptamers: new tools for targeted cancer therapy. Sun H; Zhu X; Lu PY; Rosato RR; Tan W; Zu Y Mol Ther Nucleic Acids; 2014 Aug; 3(8):e182. PubMed ID: 25093706 [TBL] [Abstract][Full Text] [Related]
10. Aptamer-siRNA chimeras for HIV. Takahashi M; Burnett JC; Rossi JJ Adv Exp Med Biol; 2015; 848():211-34. PubMed ID: 25757623 [TBL] [Abstract][Full Text] [Related]
12. Advances in Aptamers-Based Applications in Breast Cancer: Drug Delivery, Therapeutics, and Diagnostics. Gholikhani T; Kumar S; Valizadeh H; Mahdinloo S; Adibkia K; Zakeri-Milani P; Barzegar-Jalali M; Jimenez B Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430951 [TBL] [Abstract][Full Text] [Related]
13. Aptamer-iRNAs as Therapeutics for Cancer Treatment. Soldevilla MM; Meraviglia-Crivelli de Caso D; Menon AP; Pastor F Pharmaceuticals (Basel); 2018 Oct; 11(4):. PubMed ID: 30340426 [TBL] [Abstract][Full Text] [Related]
14. A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. Wang CW; Chung WH; Cheng YF; Ying NW; Peck K; Chen YT; Hung SI J Allergy Clin Immunol; 2013 Sep; 132(3):713-722.e11. PubMed ID: 23791505 [TBL] [Abstract][Full Text] [Related]
15. Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy. Zhu H; Li J; Zhang XB; Ye M; Tan W ChemMedChem; 2015 Jan; 10(1):39-45. PubMed ID: 25277749 [TBL] [Abstract][Full Text] [Related]
19. Aptamer-mediated selective delivery of short RNA therapeutics in cancer cells. Esposito CL; Catuogno S; de Franciscis V J RNAi Gene Silencing; 2014; 10():500-6. PubMed ID: 25414727 [TBL] [Abstract][Full Text] [Related]
20. Cell-specific aptamers and their conjugation with nanomaterials for targeted drug delivery. Liao J; Liu B; Liu J; Zhang J; Chen K; Liu H Expert Opin Drug Deliv; 2015 Mar; 12(3):493-506. PubMed ID: 25430795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]